Lupus & antiphospholipid syndrome
Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE
Authors' conclusion
HLA-DRB1*13 confers risk for both aPS-PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through aPS-PT. HLA-DRB1*03 was negatively associated with aPL and positively with favourable lipid levels.
Study context
- Population
- Consecutive SLE patients with information on cardiovascular risk factors, blood lipids, LA and thrombotic events
- Participants
- 341 consecutive SLE patients
- Exposure
- HLA-DRB1* alleles vs aPS-PT, conventional aPL and thrombosis
- Outcome
- Associations between aPS-PT and HLA-DRB1* alleles and thrombosis
Methodological detailsconsecutive patients, uni- and multivariate analyses
- Consecutive patients
- Uni- and multivariate analyses
Main finding
As reported in the abstract
aPS/PT antibodies associated positively with HLA-DRB1*13 (OR)
2.7
P = 0.002
Anti-β2GPI and aCL associated primarily with HLA-DRB1*04 (OR)
2.5
P = 0.0005
Observational data: associations, not effects.
Further findings
Lipid profile
- HLA-DRB1*03 associated with favourable HDL and triglyceride profile
Original publication
Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE. Rheumatology (Oxford). Published 1 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →